Alnylam Pharmaceuticals, Inc. ALNY
$239.36
+0.46%
at last close
Financials (TTM)
- Revenue
- $4.80 billion
- Net Income
- $733.11 million
- Net Margin
- 15.26%
- Return on Equity
- 54.14%
- Debt-to-Equity
- —
- P/E Ratio
- 44.57
- Price / Book
- 23.54
- Price / Sales
- 6.64
Over the trailing twelve months, Alnylam Pharmaceuticals, Inc. generated revenue of $4.80 billion and net income of $733.11 million, a net margin of 15.26%.
At the last closing price of $239.36, ALNY trades at 44.57 times trailing earnings and 6.64 times sales, with a market capitalization of $31.88 billion.
Key Stats
- Last Close
- $239.36
- Market Cap
- $31.88 billion
- 52-Week Range
- $197.81 – $495.55
- Average Volume
- 1.70 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.